Caroline Almon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Almon has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alexis Khalil
Foghorn Therapeutics Inc.; Watertown, MA, USA
23 shared publications - Alfonso Quintás-Cardama
Foghorn Therapeutics Inc.; Watertown, MA, USA
23 shared publications - Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
23 shared publications - Ashwin Kishtagari
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Nashville, TN, USA
23 shared publications - Caitlin Patriquin
Foghorn Therapeutics Inc., Cambridge, Massachusetts
23 shared publications - Courtney Denton Dinardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
23 shared publications
Latest Publications
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 2: Representativeness of Study Participants.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 2: Representativeness of Study Participants.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 3. Baseline disease characteristics of patients with R/R AML or MDS treated with FHD-286.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 3. Baseline disease characteristics of patients with R/R AML or MDS treated with FHD-286.